目的 探討骨松寶顆粒聯(lián)合依降鈣素治療骨質(zhì)疏松癥的臨床療效。方法 選取于2017年4月—2020年4月南陽(yáng)市中心醫(yī)院收治的128例骨質(zhì)疏松癥患者，根據(jù)隨機(jī)數(shù)表法分為對(duì)照組（64例）和治療組（64例）。對(duì)照組肌肉注射依降鈣素注射液，10 U/次，2次/周。治療組在對(duì)照組的基礎(chǔ)上口服骨松寶顆粒治療，5 g/次，3次/d。兩組均治療1個(gè)月。觀察兩組的臨床療效，比較兩組平均骨密度（BMD）、骨鈣素（BGP）、Ⅰ型膠原羧基末端交聯(lián)肽（β-CTX）、白介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、Oswestry功能障礙指數(shù)（ODI）評(píng)分的變化情況。結(jié)果 治療后，治療組總有效率89.06%，顯著高于對(duì)照組71.88%（P<0.05）。治療后，兩組BMD、BGP顯著升高，但β-CTX、IL-6、TNF-α顯著下降（P<0.05）；治療后，治療組BMD、BGP高于對(duì)照組，而β-CTX、IL-6、TNF-α低于對(duì)照組（P<0.05）。治療后，兩組患者ODI評(píng)分均顯著下降（P<0.05）；且治療組低于對(duì)照組（P<0.05）。結(jié)論 骨松寶顆粒聯(lián)合依降鈣素治療骨質(zhì)疏松癥療效確切，可改善骨轉(zhuǎn)換因子和炎癥細(xì)胞因子，降低ODI評(píng)分，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the effect of Gusongbao Granules combined with elcatonin in treatment of osteoporosis. Methods 128 patients with osteoporosis admitted in Nanyang Central Hospital from April 2017 to April 2020 were selected. According to the random number table method, they were divided into control group (n = 64) and treatment group (n = 64). Patients in the control group were im administered with Elcatonin Injection, 10 U/time, twice weekly. Patients in the treatment group were po administered with Gusongbao Granules on the basis of the control group, 5 g/time, three times daily. Both groups were treated for 1 month. The clinical effects of two groups were observed, and changes of average bone mineral density (BMD), osteocalcin (BGP), collagen type Ⅰ carboxyl terminal crosslinking peptide (β-CTX), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), oswestry disability index (ODI) score in two groups were compared. Results After treatment, the total effective rate of the treatment group was 89.06%, significantly higher than that of the control group (71.88%, P<0.05). After treatment, BMD and BGP were significantly increased in both groups, but β-CTX, IL-6 and TNF-α were significantly decreased (P<0.05). After treatment, BMD and BGP of the treatment group were higher than those of the control group, while β-CTX, IL-6 and TNF-α of the treatment group were lower than those of the control group (P<0.05). After treatment, ODI score of patients in both groups decreased significantly (P<0.05). ODI score in the treatment group was lower than that in the control group (P<0.05). Conclusion Gusongbao Granules combined with elcatonin has curative effect in treatment of osteoporosis, and can improve bone conversion factors and inflammatory cytokines, and also can reduce ODI score, which has certain clinical application value.

R977

河南省科技發(fā)展計(jì)劃項(xiàng)目（182102510055）